ThePigSite Latest News
Boehringer Ingelheim Adds Two to Swine Sales Team
MISSOURI - Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces the addition of Chris Beard and Douglas Skartvedt as sales representatives for the company’s swine division. Both have more than 10 years of swine health sales and production experience.
Beard most recently served as swine industry specialist for the swine business unit of Pfizer Animal Health. He received his bachelor’s degree in animal science from Purdue University, West Lafayette, Ind. Beard will service customers across the United States. As a BIVI swine division sales representative, he will provide team support in the distribution and sales of the company’s broad portfolio of swine vaccine products.
Skartvedt also served as swine industry specialist and later account manager for the swine business unit of Pfizer Animal Health. He received his bachelor’s degree in animal science from Iowa State University of Ames, Iowa. Skartvedt will serve customers in Minn. and Iowa.
“Doug and Chris’ both have extensive experience and knowledge in the swine industry, which provides a strong foundation for marketing programs directly to veterinarians and producers,” says David Gocken, national sales manager of the BIVI swine division. “We will continue to add sales support and other resources to demonstrate our commitment to the swine industry.”
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation (based in Ridgefield, Conn.), and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2004, Boehringer Ingelheim posted net sales of U.S. $10.2 billion (8.2 billion euro) while spending nearly one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
Source: Boehringer Ingelheim UK - 13th December 2004
More of the latest Pig Industry News
Zhongpin Leases New Pork Facility in China
CME: Sharp Decline in Canadian Hog Imports to US
Standards Set for Animal Feeds
Voting Starts for Alpharma Video Contest
Change in Pork Production in Demand
US, Mexican Facilities Approved for Meat Export
Conserve Energy in Hog Barns This Winter
DA: Enough Pork Supply in Bicol During Christmas
Pork CRC Helps Cut Costs and Push Production
Canada Hopes for Quick Resolution of COOL

